Search Results - technology+classifications+%3e+therapeutics+and+vaccines

8 Results

Sort By:

Pancreatic cancer patients will be treated with a PI3K inhibitor to induce the cancer cells to reveal their antigens to the immune system Background: Standard chemotherapies have little impact on pancreatic cancer (PDAC) patient survival, and new T-cell therapies have yet to be successful in treating solid tumors. Phosphoinositide 3-kinase (PI3K),...

Published: 8/26/2025 | Inventor(s): Richard Lin

Keywords(s): cancer, immunotherapy, phosphoinositide 3-kinase (PI3K), PI3K inhibitors, Technologies

Category(s): Campus > Stony Brook University, Technology Classifications, Technology Classifications > Therapeutics and Vaccines

Novel Compounds and Methods for Treating Invasive Fungal Infections

Compounds that decrease the synthesis of glucosylceramide, a sphingolipid that promotes fungal infection Background: With the increasing number of immunodeficient subjects and the increase of the lifespan of these subjects due to the advance in medicine, there has been a concomitant rise in the number of cases of life-threatening fungal infections....

Published: 8/29/2025 | Inventor(s): Maurizio Del Poeta, Visesato Mor

Keywords(s): antifungal, fungal infection, glucosylceramide, sphingolipid, Technologies

Category(s): Campus > Stony Brook University, Technology Classifications > Therapeutics and Vaccines

Prevention of Glucocorticoids-Induced Muscle Atrophy and/or Enhancement of Muscle Regeneration Via Neutrophil Elastase Inhibition

A novel therapeutic approach to treating muscular dystrophies by enhancing muscle regeneration, function and fiber size Background: Muscular dystrophy encompasses more than 30 inherited diseases characterized by muscle weakness and muscle loss. All forms of muscular dystrophy are progressive and deteriorating. At the moment, there is no cure for muscular...

Published: 8/29/2025 | Inventor(s): Addolorata Pisconti

Keywords(s):

Category(s): Campus > Stony Brook University, Technology Classifications > Therapeutics and Vaccines

Next-Generation Taxoids

Novel fluorine-containing taxoids with high potency against drug-resistant cancer. Background: Paclitaxel and docetaxel have been extensively used in clinic for treatment of various cancers. However, their lack of tumor-specificity frequently results in an assortment of undesired side effects and exhibit little efficacy in treating melanoma, pancreatic,...

Published: 8/29/2025 | Inventor(s): Iwao Ojima, Changwei Wang, Xin Wang

Keywords(s): Technologies

Category(s): Campus > Stony Brook University, Technology Classifications, Technology Classifications > Therapeutics and Vaccines

Biliverdin IXβ Reductase

Developing first-in-class therapy for patients with thrombocytopenia. Background: Thrombocytopenia is a medical condition characterized by low platelet counts. Thrombocytopenia can be brought on as a result of a separate disorder such as leukemia, an immune system problem or it can be an adverse result of taking medication, such as chemotherapy. Symptoms...

Published: 8/29/2025 | Inventor(s): Wadie Bahou, Song Wu

Keywords(s): Technologies

Category(s): Campus > Stony Brook University, Technology Classifications, Technology Classifications > Therapeutics and Vaccines

Novel Soluble Amylin Formulations for Co-injection with Insulin

Amylin variants which are much more soluble than the wild type peptide, designed to be co-formulated with insulin to treat diabetes. Background: Administration of Islet Amyloid Polypeptide IAPP with Insulin (as a separate injection) helps to normalize fluctuating glucose levels to a greater degree than is possible with insulin alone. Unfortunately,...

Published: 8/26/2025 | Inventor(s): Daniel Raleigh, Andisheh Abedini

Keywords(s): Technologies

Category(s): Campus > Stony Brook University, Technology Classifications > Therapeutics and Vaccines

Benzimidazoles and Pharmaceutical Compositions Thereof

A novel cell division inhibitor with efficacy against Mycobacterium tuberculosis Background: Multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant TB (XDR-TB) are a significant public health threat for TB control efforts. Despite efforts in last 50 years, development of new TB treatments have been limited to drug targets like...

Published: 8/29/2025 | Inventor(s): Iwao Ojima, Seung-Yub Lee

Keywords(s): Technologies

Category(s): Campus > Stony Brook University, Technology Classifications, Technology Classifications > Therapeutics and Vaccines

Inhibition of the Soluble Extracellular Domain of E-cadherin: A Novel Tumoricidal Drug for Cancers

Monoclonal antibodies that have demonstrated profound antitumor effects both in vitro and in vivo. Background: Over the last decade, the most significant revolutionary advances in oncology have been the introduction and FDA approval of targeted monoclonal antibodies (mAb) against the human epidermal growth factor receptor (HER1-4) family. In combination...

Published: 8/29/2025 | Inventor(s): Sabine Brouxhon, Stephanos Kyrkanides, Marcia Simon, Li Ma, Liqun Wang, Soosan Ghazizadeh

Keywords(s): TAF, Technologies

Category(s): Campus > Stony Brook University, Technology Classifications, Technology Classifications > Therapeutics and Vaccines